Reduced oxidative damage in ALS by high-dose enteral melatonin treatment

2006 | journal article

Jump to:Cite & Linked | Documents & Media | Details | Version history

Cite this publication

​Reduced oxidative damage in ALS by high-dose enteral melatonin treatment​
Weishaupt, J. H. ; Bartels, C. ; Pölking, E. ; Dietrich, J.; Rohde, G. ; Poeggeler, B.   & Mertens, N. et al.​ (2006) 
Journal of Pineal Research41(4) pp. 313​-323​.​ DOI: https://doi.org/10.1111/j.1600-079X.2006.00377.x 

Documents & Media

License

GRO License GRO License

Details

Authors
Weishaupt, Jochen H. ; Bartels, Claudia ; Pölking, Esther ; Dietrich, Jeannine; Rohde, Gundula ; Poeggeler, Burkhard ; Mertens, Nina; Sperling, Swetlana ; Bohn, Matthias ; Hüther, Gerald ; Schneider, Armin; Bach, Alfred; Sirén, Anna-Leena ; Hardeland, Rüdiger ; Bähr, Mathias ; Nave, Klaus-Armin ; Ehrenreich, Hannelore 
Abstract
Amyotrophic lateral sclerosis (ALS) is the collective term for a fatal motoneuron disease of different etiologies, with oxidative stress as a common molecular denominator of disease progression. Melatonin is an amphiphilic molecule with a unique spectrum of antioxidative effects not conveyed by classical antioxidants. In preparation of a possible future clinical trial, we explored the potential of melatonin as neuroprotective compound and antioxidant in: (1) cultured motoneuronal cells (NSC-34), (2) a genetic mouse model of ALS (SOD1(G93A)-transgenic mice), and (3) a group of 31 patients with sporadic ALS. We found that melatonin attenuates glutamate-induced cell death of cultured motoneurons. In SOD1(G93A)-transgenic mice, high-dose oral melatonin delayed disease progression and extended survival. In a clinical safety study, chronic high-dose (300 mg/day) rectal melatonin was well tolerated during an observation period of up to 2 yr. Importantly, circulating serum protein carbonyls, which provide a surrogate marker for oxidative stress, were elevated in ALS patients, but were normalized to control values by melatonin treatment. This combination of preclinical effectiveness and proven safety in humans suggests that high-dose melatonin is suitable for clinical trials aimed at neuroprotection through antioxidation in ALS.
Issue Date
2006
Journal
Journal of Pineal Research 
ISSN
0742-3098
Language
English

Reference

Citations


Social Media